Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies

Mathieu Ferrari, Farhaan Parekh, Paul Maciocia, Pedro Horna, Simon Thomas, Andrew K. Sewell and Martin Pule ()
Additional contact information
Mathieu Ferrari: Autolus Therapeutics
Farhaan Parekh: Autolus Therapeutics
Paul Maciocia: University College London
Pedro Horna: Mayo Clinic
Simon Thomas: Autolus Therapeutics
Andrew K. Sewell: Cardiff University School of Medicine
Martin Pule: Autolus Therapeutics

Nature Communications, 2025, vol. 16, issue 1, 1-4

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-56396-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-56396-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-56396-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().